The companies will collaborate on the development of dual amylin calcitonin receptor agonists for patients with Type 2 diabetes.
Eli Lilly and KeyBioscience AG are teaming up on the development of dual amylin calcitonin receptor agonists (DACRAs), a potential new class of treatments for metabolic disorders such as Type 2 diabetes, the companies said in a June 8, 2017 statement. According to the terms of the agreement, Lilly will pay KeyBioscience an initial $55 million, with the potential for milestone and tiered royalty payments on future sales.
In a statement, the companies said that the collaboration includes access to the DACRA platform with multiple molecules including KBP-042, KBP-089, and KBP-056. Lilly will receive worldwide rights to develop and commercialize these molecules. KeyBioscience has initiated Phase II development with KBP-042. Other assets included in the collaboration, engineered for differences in effect or potency, range from Phase I to pre-clinical. The dual activation of calcitonin and amylin receptors is thought to improve insulin sensitivity, suppress food intake, reduce fat deposition, improve blood glucose levels, and cause weight reduction in patients with Type 2 diabetes.
Source: Eli Lilly
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.